Anavex Life Sciences Corp (AVXL)

[nidan7500]

I am tempted to declare 21 June, 2022 to be TRIFECTA DAY. We also need to keep in mind that 99% of all AD trials fail. So, maybe we have some kind of STEALTH CNS Diseases celebration being planned. Pretty clever to be the only planned CNS disease event on a day when WS is shut down.

NEW YORK – August 12, 2021

Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, today reported financial results for its fiscal quarter ended June 30, 2021.


“We are pleased with the rigorous and efficient execution of the confirmatory late-stage Precision Medicine ANAVEX®2-73 Phase 2b/3 randomized, double-blind, placebo-controlled clinical trial with a total of 509 patients with Alzheimer’s disease and are excited to be able to provide top-line data by 2H 2022. The steadfast clinical trial execution capabilities of the Anavex team also extend to the Precision Medicine ANAVEX®2-73 Phase 2/3 AVATAR clinical trial in patients with Rett syndrome, which exceeded the enrollment target, and currently topline results from this study are expected by 2H 2021,” said Christopher U Missling, PhD, President and Chief Executive Officer of Anavex. “We are excited about the potential of our SIGMAR1 platform, and we continue working to advance new programs to the clinic, all with the aim of meeting the unmet clinical needs of patients with both degenerative and developmental neurological disorders around the world.”

https://www.anavex.com/post/anavexlifesciencesprovidesbusinessupdateandreportsfiscal2021thirdquarterfinancialresult